UNSPSC 51432902: Fosinopril

This classification denotes an ace inhibitor with the molecular formula C30H46NO7P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R43D2573WO, chemically known as l-proline, 4-cyclohexyl-1-(((2-methyl-1-(1-oxopropoxy)propoxy)(4-phenylbutyl)phosphinyl)acetyl)-, (2alpha,4beta)- but generally known as fosinopril, which bears US NIH Compound Identifier 55891. European Medicines Agency schedules Fosinopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13918MIG.

UNSPSC 51432902 Fosinopril is a Commodity code for a specific angiotensin-converting enzyme (ACE) inhibitor pharmaceutical used in emergency medical and health plan settings. State and local governments procure fosinopril and related advanced life support medications through fire-rescue departments, county health agencies, and multistate cooperative purchasing consortia. The work involves supplying individual units or bulk quantities of the drug to meet clinical demand, with vendors managing inventory rotation, expiration tracking, and delivery logistics tied to standing orders or call-in fulfillment. Issuing bodies include municipal fire departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across dozens of participating jurisdictions. Recent activity shows municipal procurement (Tampa Fire Rescue through the City of Tampa's Purchasing Department), state-level health commission market research (Texas Health and Human Services Commission), and multistate cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota and Oregon).

Activity is concentrated in Florida, Texas, and Minnesota as of early 2026. The City of Tampa issued an IFB (Bid No. 26-P-00188) for Advanced Life Support Medications including fosinopril-adjacent products (Labetalol, Epinephrine, Adenosine, and Diltiazem), due April 8, 2026, with an estimated contract value of $40,000.00 and a one-year term plus renewal options; the bid was sheltered to Small Local Business Enterprises with a 5 percent discount. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013) on March 27, 2026, to explore direct-to-manufacturer pharmaceutical supply models outside traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendors to supply through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson), with contract awards effective July 1, 2026, for a two-year initial term. All three opportunities reflect state and local demand for reliable, expiration-controlled pharmaceutical supply chains integrated into emergency response and health plan operations.